Lars Jonsson, M.D., Ph.D., Chairman of the board
Lars Jonsson is MD and has a PhD in anesthesia and intensive care. In addition to a long-term clinical and academic experience, Lars Jonsson has since 1998 been CEO at Uppsala University holding company, UUAB, which works with commercialization of research. As a result, he has been involved in over 90 start-ups and spin-outs from Uppsala University, many of which he has had board and chairman positions.
Lars Jonsson can be reached on telephone +46-70-626 99 30.
Jarl Wikberg, M.D., Ph.D., Board member
Jarl Wikberg is MD and has a doctorate from Linköping University in Medical Pharmacology. He has a long academic experience holding research and teaching positions at several universities. Presently he holds a part time position as senior professor of Pharmaceutical Pharmacology at Uppsala University. On top of this Jarl Wikberg is the founder of several companies relating to the pharmaceutical industry. Wikberg has a long experience in research and has extensive scientific production. Wikberg is the founder of Dicot and the discoverer of LibiguinTM. In addition to his work as a member of the Board, he is Chief Scientific Officer in Dicot.
Lena Söderström, M.Sc., Board member
Lena Söderström holds a M.Sc. in medical science from Uppsala University as well as an Executive MBA from the same university. Lena Söderström is President of Senzime and has 30 years of experience from senior positions in international pharmaceutical and medical technology companies. She has extensive experience from leading positions in project management, business development, international marketing and manufacturing. She is a representative of the Stockholm Chamber of Commerce, and board member of Uppsala University Holding AB (UUAB) and SLU Holding AB.
Mikael von Euler, M.D., Ph.D., Board member
Mikael von Euler has a doctorate at Karolinska Institutet in Stockholm. Dr. von Euler is an oncologist with more than 25 years experience in the pharmaceutical industry. He was previously CMO at Oncos Therapeutics (now Targovax) and Chief Medical Officer and SVP at Aprea Therapeutics. Dr. von Euler has had several senior positions in major pharmaceutical companies: Cluster Head at Roche / Genentech, Vice President Oncology Europe at GlaxoSmithKline, and Global Product Director for Arimidex / Nolvadex at AstraZeneca.
Ebba Florin-Robertsson, Styrelseledamot
Göran Beijer, M.C.E., CEO
Göran Beijer is CEO of Dicot and heads Dicot's management team. He has more than 30 years experience from the Life Sciences, with experience in production, research, business development and management. Göran Beijer has worked in Dicot since 2016/17 and since April 2018 as CEO..
Göran Beijer can be reached on telephone +46-70-663 60 09.
Jarl Wikberg, M.D., Ph.D., CSO
Jarl Wikberg is Chief Scientific Officer (CSO) of Dicot. Jarl Wikberg is the discoverer of LibiguinTM, now in development of Dicot. He has a long-standing scientific background in Pharmacology and Drug Development, with well over 300 scientific publications, including articles, reviews, book chapters and books, and many accepted drug patents. He has a long-standing experience from both the pharmacy industry and academia. In Dicot, Jarl Wikberg is leading the scientific developments of LibiguinTM, in particular in relation to pharmacology and biology.
Julie Silber, Director of Investor Relations
Julie Silber brings over 20+ years of financial experience including executive financial leadership roles with both private and publicly held companies, four+ years of CFO level experience, several years as a for-hire equity analyst and over 10+ years as an IRO. Since moving to Sweden, Julie has specialized in gaining visibility and positioning smaller, Life Science companies to the global financial markets. She holds a bachelor's degree in International Relations from the University of Southern California, a certificate in Accounting from the Center for Non-Profit Management and a Master’s degree in Environmental Science & Policy, also from USC.
Maria Wanderoy, COO
Maria är Chief Operating Officer (COO) i Dicot. Maria har en Filosofie Doktor (PhD) examen från Stockholms Universitet inom Neurokemi och Neorotoxikologi. Hon har över 20 års erfarenhet av läkemedelsutveckling från läkemedelsindustrin där Maria har haft ett antal olika roller som tex Global Projektledare, Klinisk Projektledare och Preklinisk Projektledare samt tidigare i karriären som Senior Research Scientist. Detta ger Maria en bred erfarenhet av läkemedelsutveckling som spänner från tidig preklinisk forskning och vägen fram till klinisk fas till att leda kliniska program med planering och genomförande av Fas 1, 2 och 3 studier.
Jessica Roxhed, CFO
Jessica brings over 15 years of corporate finance experience to Dicot AB, including Chief Financial Officer with broad experience in business administration and holding any other senior management positions in companies in various industries. Prior to joining Dicot, Jessica was the CFO of Senzime AB. Prior to that, Jessica served as the Controller for many companies, including Svenska kyrkan nationell nivå, Spoon Publishing AB, Vattenfall Service Nordic AB. She received her Master of Science in Business administration from the University of Uppsala.
Kerstin Fugl-Meyer, Professor, Ph.D., Key Opinon Leader
Kerstin Fugl-Meyer us Adjunct Professor of Social Work, especially Clinical Sexology, at the Department of Neurobiology, Care Sciences and Society of the Karolinska Institute, Stockholm, Sweden. She is a productive researcher with 140 scientific publications and has worked in clinical research including participating in clinical trials. Professor Fugl-Meyer is enrolled as Key Opinon Leader for Dicot on consultancy basis, giving advice in the areas of Sexology, Clinical Trials and aiding Dicot in setting up Clinical Networks.
Elin Gahm, Medical Doctor
Lars Kylberg, Authorized Public Accountant
Lars Kylberg, PwC Sweden, is Auditor for Dicot. He has over 20 years of experience in auditing. He has been an auditor in Dicot AB since 2017. Lars Kylberg has extensive experience from both development companies and companies whose shares are listed or admitted to trading.